Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Sotatercept

Research Leaders

5 sponsors active, led by National Cancer Institute (NCI)

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 2 (1)

Trial Status

Not Yet Recruiting1
Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05557708Early Phase 1Not Yet Recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

NCT01284348Phase 2Terminated

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

NCT00923884Completed

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Sotatercept1
  • 212lead Pentixather1
  • 203lead Pentixather Spectct1

Active Sponsors

  • National Cancer Institute (NCI)2
  • Holden Comprehensive Cancer Center1
  • Merck Sharp & Dohme LLC1
  • National Institutes of Health (NIH)1
  • Yusuf Menda1

Top Investigators

Related Conditions

  • Neuroendocrine Tumor Of The Lung1
  • Cancer Of Head And Neck1
  • Anemia1
  • Carcinoma Nonsmallcell Lung1
  • Bladder Cancer1

Activity Timeline